Company Overview and News

 
NSW riled by lack of 'fit and proper' for offshore gas exploration

2018-04-13 smh.com.au
Companies exploring for energy off the NSW coast should be subject to the same "fit and proper person test" as those on land, the Berejiklian government says, underscoring tensions between Sydney and Canberra over the approval of seismic testing in waters near Newcastle.

 
MEC Resources investee will undertake seismic survey off coast near Newcastle

2018-03-29 proactiveinvestors.com.au
MEC RESOURCES LIMITED (ASX:MMR) investee Advent Energy Ltd will undertake a seismic survey early next month over the Baleen prospect in PEP11 offshore of Newcastle in New South Wales.

 
Grandbridge Ltd to reveal board change

2016-11-24 proactiveinvestors.com.au
The halt will remain in place until the opening of trade on Monday 28th November 2016, or earlier if an announcement is made to the market.

 
Advent Pushes Ahead with Seismic Campaign in PEP 11 in Sydney Basin

2016-07-19 rigzone
MEC Resources Ltd. reported Tuesday that Advent Energy Pty Ltd., operator of the PEP 11 project in the offshore Sydney Basin in Australia, is pushing ahead with a seismic campaign around a key potential drilling prospect in the exploration permit.

 
Advent's RL1 Project in Australia's NT to Gain from Infrastructure Project

2016-06-23 rigzone
MEC Resources Ltd. reported Thursday that its oil and gas exploration unit Advent Energy Ltd.'s 100 percent owned RL1 (Weaber Gas Field) Project in Australia's Northern Territory will potentially benefit from a government infrastructure funding program in the state, according to a press release.

 
MEC Updates on PEP11 Planned Seismic Program in Offshore Sydney Basin

2016-05-19 rigzone
MEC Resources Ltd. provided Thursday the following update in relation to the planned seismic program within PEP11, in the offshore Sydney Basin, Australia.

 
MEC Says Seismic Survey Being Planned for PEP11 Offshore Australia

2016-05-17 rigzone
MEC Resources Ltd. reported Monday that in relation to the proposed exploration works by Advent Energy Ltd. within PEP11 in the offshore Sydney Basin, Australia.

 
Advent Contracts Vessel for 2D Seismic Survey in PEP11 in Sydney Basin

2016-04-14 rigzone
Advent Energy Ltd., an unlisted oil and gas exploration firm owned by major shareholders MEC Resources, BPH Energy, Grandbridge and Talbot Group Investments, provided Thursday the following announcement regarding the execution of the contract for the seismic activities within PEP 11 in the offshore Sydney Basin, offshore Australia.

 
Trading Halt

2016-04-13 asx.com.au

 
MEC Resources announces proposed exploration works within PEP11, offshore Sydney Basin

2016-03-24 oilvoice
MEC Resources Ltd (ASX: MMR) is pleased to provide the following summary of the proposed exploration works within PEP11 in the offshore Sydney Basin. A revised future drill target was announced in September 2015. This report identified a revised drill target on the Baleen prospect on seismic line B4 - 18 with a total depth of 2150 metres. The report identified that the nearest equivalent depth/age/commercial gas - condensate fields are located in the Bowen Basin, south - east Queensland.

 
 
Australia's Advent Signs LOI for Potential Gas Supply to Northern Minerals

2016-03-21 rigzone
MEC Resources Ltd. disclosed Monday that investee Advent Energy Limited (Advent) has signed a Letter of Intent (LOI) with Northern Minerals for potential future supply of gas to their Browns Range heavy rare earth element project in north-eastern Western Australia.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...